SAN DIEGO, Feb. 24, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...
LA JOLLA, Calif. -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that ...
LA JOLLA, Calif., Feb. 13, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, ...
VANCOUVER, BC / ACCESSWIRE / July 6, 2023 / Regulus Resources Inc. ("Regulus" or the "Company", TSX-V:REG, OTCQX:RGLSF) is pleased to announce positive extraction rates on mineralization from the ...
SAN DIEGO (AP) — SAN DIEGO (AP) — Regulus Therapeutics Inc. (RGLS) on Tuesday reported a loss of $7 million in its second quarter. On a per-share basis, the San Diego-based company said it had a loss ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback